ID   CPT1C_HUMAN             Reviewed;         803 AA.
AC   Q8TCG5; A8K0Z8; Q5K6N5; Q8N6Q9; Q8NDS6; Q8TE84;
DT   05-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   28-JAN-2026, entry version 174.
DE   RecName: Full=Palmitoyl thioesterase CPT1C {ECO:0000305};
DE            EC=3.1.2.22 {ECO:0000269|PubMed:30135643};
DE   AltName: Full=Carnitine O-palmitoyltransferase 1, brain isoform;
DE            Short=CPTI-B;
DE   AltName: Full=Carnitine palmitoyltransferase 1C;
DE   AltName: Full=Carnitine palmitoyltransferase I {ECO:0000303|PubMed:12376098};
DE            Short=CPT I-C {ECO:0000303|PubMed:12376098};
GN   Name=CPT1C {ECO:0000312|HGNC:HGNC:18540}; Synonyms=CATL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Eye;
RX   PubMed=12376098; DOI=10.1006/geno.2002.6845;
RA   Price N., van der Leij F.R., Jackson V., Corstorphine C., Thomson R.,
RA   Sorensen A., Zammit V.;
RT   "A novel brain-expressed protein related to carnitine palmitoyltransferase
RT   I.";
RL   Genomics 80:433-442(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Scorilas A., Katsaros N.;
RT   "Molecular characterization, chromosomal localization and expression
RT   analysis of a gene, CATL1, encoding for a new member of the human carnitine
RT   acyltransferase family.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Kidney epithelium, and Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 375-803 (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION, CAUTION, MUTAGENESIS OF HIS-470, AND MALONYL-COA BINDING.
RX   PubMed=16651524; DOI=10.1073/pnas.0602205103;
RA   Wolfgang M.J., Kurama T., Dai Y., Suwa A., Asaumi M., Matsumoto S.,
RA   Cha S.H., Shimokawa T., Lane M.D.;
RT   "The brain-specific carnitine palmitoyltransferase-1c regulates energy
RT   homeostasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7282-7287(2006).
RN   [8]
RP   REVIEW OF FUNCTION.
RX   PubMed=26708865; DOI=10.1016/j.plipres.2015.11.004;
RA   Casals N., Zammit V., Herrero L., Fado R., Rodriguez-Rodriguez R.,
RA   Serra D.;
RT   "Carnitine palmitoyltransferase 1C: From cognition to cancer.";
RL   Prog. Lipid Res. 61:134-148(2016).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF SER-252; HIS-470 AND ASP-474,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH AMPAR COMPLEX.
RX   PubMed=30135643; DOI=10.3389/fnmol.2018.00275;
RA   Gratacos-Batlle E., Olivella M., Sanchez-Fernandez N., Yefimenko N.,
RA   Miguez-Cabello F., Fado R., Casals N., Gasull X., Ambrosio S., Soto D.;
RT   "Mechanisms of CPT1C-Dependent AMPAR Trafficking Enhancement.";
RL   Front. Mol. Neurosci. 11:275-275(2018).
RN   [10] {ECO:0007744|PDB:2M76}
RP   STRUCTURE BY NMR OF 1-50, AND DOMAIN.
RX   PubMed=24037959; DOI=10.1002/bip.22396;
RA   Samanta S., Situ A.J., Ulmer T.S.;
RT   "Structural characterization of the regulatory domain of brain carnitine
RT   palmitoyltransferase 1.";
RL   Biopolymers 101:398-405(2014).
RN   [11]
RP   INVOLVEMENT IN SPG73, VARIANT SPG73 CYS-37, CHARACTERIZATION OF VARIANT
RP   SPG73 CYS-37, FUNCTION, INTERACTION WITH ATL1, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=25751282; DOI=10.1001/jamaneurol.2014.4769;
RA   Rinaldi C., Schmidt T., Situ A.J., Johnson J.O., Lee P.R., Chen K.L.,
RA   Bott L.C., Fado R., Harmison G.H., Parodi S., Grunseich C., Renvoise B.,
RA   Biesecker L.G., De Michele G., Santorelli F.M., Filla A., Stevanin G.,
RA   Duerr A., Brice A., Casals N., Traynor B.J., Blackstone C., Ulmer T.S.,
RA   Fischbeck K.H.;
RT   "Mutation in CPT1C Associated with pure autosomal dominant spastic
RT   paraplegia.";
RL   JAMA Neurol. 72:561-570(2015).
RN   [12]
RP   ERRATUM OF PUBMED:25751282.
RX   PubMed=25961183; DOI=10.1001/jamaneurol.2015.0528;
RA   Rinaldi C., Schmidt T., Situ A.J., Johnson J.O., Lee P.R., Chen K.L.,
RA   Bott L.C., Fado R., Harmison G.H., Parodi S., Grunseich C., Renvoise B.,
RA   Biesecker L.G., De Michele G., Santorelli F.M., Filla A., Stevanin G.,
RA   Duerr A., Brice A., Casals N., Traynor B.J., Blackstone C., Ulmer T.S.,
RA   Fischbeck K.H.;
RT   "Typographical errors in figure.";
RL   JAMA Neurol. 72:608-608(2015).
CC   -!- FUNCTION: Palmitoyl thioesterase specifically expressed in the
CC       endoplasmic reticulum of neurons. Modulates the trafficking of the
CC       glutamate receptor, AMPAR, to plasma membrane through depalmitoylation
CC       of GRIA1 (PubMed:30135643). Also regulates AMPR trafficking through the
CC       regulation of SACM1L phosphatidylinositol-3-phosphatase activity by
CC       interaction in a malonyl-CoA dependent manner (By similarity). Binds
CC       malonyl-CoA and couples malonyl-CoA to ceramide levels, necessary for
CC       proper spine maturation and contributing to systemic energy homeostasis
CC       and appetite control (PubMed:16651524). Binds to palmitoyl-CoA, but
CC       does not have carnitine palmitoyltransferase 1 catalytic activity or at
CC       very low levels (PubMed:25751282, PubMed:30135643).
CC       {ECO:0000250|UniProtKB:Q8BGD5, ECO:0000269|PubMed:16651524,
CC       ECO:0000269|PubMed:25751282, ECO:0000269|PubMed:30135643}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-hexadecanoyl-L-cysteinyl-[protein] + H2O = L-cysteinyl-
CC         [protein] + hexadecanoate + H(+); Xref=Rhea:RHEA:19233, Rhea:RHEA-
CC         COMP:10131, Rhea:RHEA-COMP:11032, ChEBI:CHEBI:7896,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:74151; EC=3.1.2.22;
CC         Evidence={ECO:0000269|PubMed:30135643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19234;
CC         Evidence={ECO:0000269|PubMed:30135643};
CC   -!- SUBUNIT: Peripherally associated with AMPAR complex. AMPAR complex
CC       consists of an inner core made of 4 pore-forming GluA/GRIA proteins
CC       (GRIA1, GRIA2, GRIA3 and GRIA4) and 4 major auxiliary subunits arranged
CC       in a twofold symmetry. One of the two pairs of distinct binding sites
CC       is occupied either by CNIH2, CNIH3 or CACNG2, CACNG3. The other harbors
CC       CACNG2, CACNG3, CACNG4, CACNG8 or GSG1L. This inner core of AMPAR
CC       complex is complemented by outer core constituents binding directly to
CC       the GluA/GRIA proteins at sites distinct from the interaction sites of
CC       the inner core constituents. Outer core constituents include at least
CC       PRRT1, PRRT2, CKAMP44/SHISA9, FRRS1L and NRN1. The proteins of the
CC       inner and outer core serve as a platform for other, more peripherally
CC       associated AMPAR constituents, including CPT1C. Alone or in
CC       combination, these auxiliary subunits control the gating and
CC       pharmacology of the AMPAR complex and profoundly impact their
CC       biogenesis and protein processing (PubMed:30135643). Interacts with
CC       SACM1L; the interaction regulates SACM1L phosphatidylinositol-3-
CC       phosphatase activity and translocation to endoplasmic reticulum/trans
CC       Golgi network in a malonyl-CoA dependent manner (By similarity).
CC       Interacts with ATL1 (PubMed:25751282). {ECO:0000250|UniProtKB:Q8BGD5,
CC       ECO:0000269|PubMed:25751282, ECO:0000269|PubMed:30135643}.
CC   -!- SUBCELLULAR LOCATION: Cell projection, dendrite
CC       {ECO:0000269|PubMed:25751282}. Cell projection, axon
CC       {ECO:0000269|PubMed:25751282}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:30135643}; Multi-pass membrane protein
CC       {ECO:0000255}. Note=Localized in the soma and dendritic and axonal
CC       projections. {ECO:0000269|PubMed:25751282}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8TCG5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TCG5-2; Sequence=VSP_010677;
CC       Name=3;
CC         IsoId=Q8TCG5-3; Sequence=VSP_012457;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in brain and testis.
CC       Expressed in motor neurons. {ECO:0000269|PubMed:12376098,
CC       ECO:0000269|PubMed:25751282}.
CC   -!- DOMAIN: CPT1 enzymes are comprised of an N-terminal regulatory domain
CC       and a C-terminal catalytic domain that are separated by two
CC       transmembrane helices. In CPT1A, the regulatory domain, termed N,
CC       adopts a malonyl-CoA inhibitory and non-inhibitory state, Nalpha and
CC       Nbeta, respectively, which differ in their association with the
CC       catalytic domain. In CPT1C, the inhibitory Nalpha state is structurally
CC       homolog whereas the non-inhibitory Nbeta state is severely destabilized
CC       which probably contributes to the low catalytic activity of CPT1C
CC       relative to CPT1A and makes its association with the catalytic domain
CC       unlikely. {ECO:0000269|PubMed:24037959}.
CC   -!- DISEASE: Spastic paraplegia 73, autosomal dominant (SPG73)
CC       [MIM:616282]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness and
CC       spasticity of the lower limbs. Rate of progression and the severity of
CC       symptoms are quite variable. Initial symptoms may include difficulty
CC       with balance, weakness and stiffness in the legs, muscle spasms, and
CC       dragging the toes when walking. In some forms of the disorder, bladder
CC       symptoms (such as incontinence) may appear, or the weakness and
CC       stiffness may spread to other parts of the body.
CC       {ECO:0000269|PubMed:25751282}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the carnitine/choline acetyltransferase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: In contrast to its paralogs, CPT1A and CPT1B, does not have,
CC       or at very low levels, carnitine O-palmitoyltransferase activity
CC       (EC:2.3.1.21) in vivo, being unable to catalyze the transfer of the
CC       acyl group of long-chain fatty acid-CoA conjugates onto carnitine. This
CC       is in agreement with its expression specific to neurons which is a
CC       cell-type that does not use fatty acids as fuel to any major extent and
CC       the fact that it locates to endoplasmic reticulum instead of
CC       mitochondria. {ECO:0000269|PubMed:12376098,
CC       ECO:0000269|PubMed:30135643}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB85068.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD38561.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF357970; AAL99615.1; -; mRNA.
DR   EMBL; AF331918; AAQ14875.1; -; Genomic_DNA.
DR   EMBL; AK074389; BAB85068.1; ALT_INIT; mRNA.
DR   EMBL; AK289713; BAF82402.1; -; mRNA.
DR   EMBL; AK290092; BAF82781.1; -; mRNA.
DR   EMBL; CH471177; EAW52524.1; -; Genomic_DNA.
DR   EMBL; BC029104; AAH29104.1; -; mRNA.
DR   EMBL; AL831876; CAD38561.2; ALT_INIT; mRNA.
DR   CCDS; CCDS12779.1; -. [Q8TCG5-1]
DR   CCDS; CCDS46147.1; -. [Q8TCG5-2]
DR   RefSeq; NP_001129524.1; NM_001136052.3. [Q8TCG5-2]
DR   RefSeq; NP_001186681.1; NM_001199752.3. [Q8TCG5-1]
DR   RefSeq; NP_001186682.1; NM_001199753.2. [Q8TCG5-1]
DR   RefSeq; NP_001365412.1; NM_001378483.1. [Q8TCG5-1]
DR   RefSeq; NP_001365413.1; NM_001378484.1. [Q8TCG5-1]
DR   RefSeq; NP_001365414.1; NM_001378485.1. [Q8TCG5-2]
DR   RefSeq; NP_689572.1; NM_152359.3. [Q8TCG5-1]
DR   RefSeq; XP_047294112.1; XM_047438156.1. [Q8TCG5-1]
DR   RefSeq; XP_047294113.1; XM_047438157.1. [Q8TCG5-1]
DR   RefSeq; XP_047294114.1; XM_047438158.1. [Q8TCG5-2]
DR   RefSeq; XP_047294115.1; XM_047438159.1. [Q8TCG5-2]
DR   RefSeq; XP_054175753.1; XM_054319778.1. [Q8TCG5-1]
DR   RefSeq; XP_054175754.1; XM_054319779.1. [Q8TCG5-1]
DR   RefSeq; XP_054175755.1; XM_054319780.1. [Q8TCG5-2]
DR   RefSeq; XP_054175756.1; XM_054319781.1. [Q8TCG5-2]
DR   PDB; 2M76; NMR; -; A=1-50.
DR   PDBsum; 2M76; -.
DR   AlphaFoldDB; Q8TCG5; -.
DR   BMRB; Q8TCG5; -.
DR   SMR; Q8TCG5; -.
DR   BioGRID; 125958; 7.
DR   FunCoup; Q8TCG5; 602.
DR   IntAct; Q8TCG5; 1.
DR   STRING; 9606.ENSP00000376303; -.
DR   GlyGen; Q8TCG5; 1 site.
DR   iPTMnet; Q8TCG5; -.
DR   PhosphoSitePlus; Q8TCG5; -.
DR   SwissPalm; Q8TCG5; -.
DR   BioMuta; CPT1C; -.
DR   DMDM; 57013809; -.
DR   jPOST; Q8TCG5; -.
DR   MassIVE; Q8TCG5; -.
DR   PaxDb; 9606-ENSP00000376303; -.
DR   PeptideAtlas; Q8TCG5; -.
DR   ProteomicsDB; 74135; -. [Q8TCG5-1]
DR   ProteomicsDB; 74136; -. [Q8TCG5-2]
DR   ProteomicsDB; 74137; -. [Q8TCG5-3]
DR   Antibodypedia; 3052; 263 antibodies from 32 providers.
DR   DNASU; 126129; -.
DR   Ensembl; ENST00000323446.9; ENSP00000319343.4; ENSG00000169169.16. [Q8TCG5-1]
DR   Ensembl; ENST00000392518.8; ENSP00000376303.4; ENSG00000169169.16. [Q8TCG5-1]
DR   Ensembl; ENST00000405931.6; ENSP00000384465.2; ENSG00000169169.16. [Q8TCG5-2]
DR   Ensembl; ENST00000598293.6; ENSP00000473028.1; ENSG00000169169.16. [Q8TCG5-1]
DR   GeneID; 126129; -.
DR   KEGG; hsa:126129; -.
DR   MANE-Select; ENST00000598293.6; ENSP00000473028.1; NM_001199753.2; NP_001186682.1.
DR   UCSC; uc002ppj.4; human. [Q8TCG5-1]
DR   AGR; HGNC:18540; -.
DR   ClinPGx; PA134922321; -.
DR   CTD; 126129; -.
DR   DisGeNET; 126129; -.
DR   GeneCards; CPT1C; -.
DR   HGNC; HGNC:18540; CPT1C.
DR   HPA; ENSG00000169169; Tissue enhanced (brain, choroid plexus, pituitary gland).
DR   MalaCards; CPT1C; -.
DR   MIM; 608846; gene.
DR   MIM; 616282; phenotype.
DR   OpenTargets; ENSG00000169169; -.
DR   Orphanet; 444099; Autosomal dominant spastic paraplegia type 73.
DR   VEuPathDB; HostDB:ENSG00000169169; -.
DR   eggNOG; KOG3716; Eukaryota.
DR   GeneTree; ENSGT01150000286917; -.
DR   HOGENOM; CLU_013513_2_1_1; -.
DR   InParanoid; Q8TCG5; -.
DR   OMA; VYSEQWQ; -.
DR   OrthoDB; 240216at2759; -.
DR   PAN-GO; Q8TCG5; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; Q8TCG5; -.
DR   BioCyc; MetaCyc:HS09892-MONOMER; -.
DR   BRENDA; 2.3.1.21; 2681.
DR   PathwayCommons; Q8TCG5; -.
DR   SignaLink; Q8TCG5; -.
DR   SIGNOR; Q8TCG5; -.
DR   Agora; ENSG00000169169; -.
DR   BioGRID-ORCS; 126129; 13 hits in 1154 CRISPR screens.
DR   ChiTaRS; CPT1C; human.
DR   EvolutionaryTrace; Q8TCG5; -.
DR   GenomeRNAi; 126129; -.
DR   Pharos; Q8TCG5; Tbio.
DR   PRO; PR:Q8TCG5; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8TCG5; protein.
DR   Bgee; ENSG00000169169; Expressed in right hemisphere of cerebellum and 124 other cell types or tissues.
DR   ExpressionAtlas; Q8TCG5; baseline and differential.
DR   GO; GO:0032281; C:AMPA glutamate receptor complex; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0098794; C:postsynapse; IEA:Ensembl.
DR   GO; GO:0016746; F:acyltransferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008474; F:palmitoyl-(protein) hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0009437; P:carnitine metabolic process; IBA:GO_Central.
DR   GO; GO:0006631; P:fatty acid metabolic process; IBA:GO_Central.
DR   GO; GO:0099072; P:regulation of postsynaptic membrane neurotransmitter receptor levels; IEA:Ensembl.
DR   FunFam; 3.30.559.70:FF:000008; carnitine O-palmitoyltransferase 1, brain isoform; 1.
DR   FunFam; 3.30.559.10:FF:000002; carnitine O-palmitoyltransferase 1, liver isoform; 1.
DR   Gene3D; 6.10.250.1760; -; 1.
DR   Gene3D; 3.30.559.10; Chloramphenicol acetyltransferase-like domain; 1.
DR   Gene3D; 3.30.559.70; Choline/Carnitine o-acyltransferase, domain 2; 1.
DR   InterPro; IPR000542; Carn_acyl_trans.
DR   InterPro; IPR023213; CAT-like_dom_sf.
DR   InterPro; IPR039551; Cho/carn_acyl_trans.
DR   InterPro; IPR042231; Cho/carn_acyl_trans_2.
DR   InterPro; IPR032476; CPT_N.
DR   PANTHER; PTHR22589; CARNITINE O-ACYLTRANSFERASE; 1.
DR   PANTHER; PTHR22589:SF55; CARNITINE O-PALMITOYLTRANSFERASE 1, BRAIN ISOFORM; 1.
DR   Pfam; PF00755; Carn_acyltransf; 1.
DR   Pfam; PF16484; CPT_N; 1.
DR   SUPFAM; SSF52777; CoA-dependent acyltransferases; 2.
DR   PROSITE; PS00439; ACYLTRANSF_C_1; 1.
DR   PROSITE; PS00440; ACYLTRANSF_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Alternative splicing; Cell projection;
KW   Disease variant; Endoplasmic reticulum; Fatty acid metabolism;
KW   Hereditary spastic paraplegia; Hydrolase; Lipid metabolism; Membrane;
KW   Neurodegeneration; Proteomics identification; Reference proteome;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..803
FT                   /note="Palmitoyl thioesterase CPT1C"
FT                   /id="PRO_0000210166"
FT   TOPO_DOM        1..52
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        53..75
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        76..103
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        104..126
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        127..803
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          761..803
FT                   /note="Required for interaction with GRIA1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BGD5"
FT   REGION          772..803
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        788..803
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        470
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:30135643"
FT   BINDING         552..564
FT                   /ligand="CoA"
FT                   /ligand_id="ChEBI:CHEBI:57287"
FT                   /evidence="ECO:0000250|UniProtKB:P18886"
FT   BINDING         586
FT                   /ligand="(R)-carnitine"
FT                   /ligand_id="ChEBI:CHEBI:16347"
FT                   /evidence="ECO:0000250|UniProtKB:P18886"
FT   BINDING         588
FT                   /ligand="(R)-carnitine"
FT                   /ligand_id="ChEBI:CHEBI:16347"
FT                   /evidence="ECO:0000250|UniProtKB:P18886"
FT   BINDING         599
FT                   /ligand="(R)-carnitine"
FT                   /ligand_id="ChEBI:CHEBI:16347"
FT                   /evidence="ECO:0000250|UniProtKB:P18886"
FT   VAR_SEQ         258..268
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010677"
FT   VAR_SEQ         623..711
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_012457"
FT   VARIANT         37
FT                   /note="R -> C (in SPG73; alters protein conformation;
FT                   dominant negative mutation; dbSNP:rs786204767)"
FT                   /evidence="ECO:0000269|PubMed:25751282"
FT                   /id="VAR_073433"
FT   MUTAGEN         252
FT                   /note="S->A: Loss of palmitoyl thioesterase activity."
FT                   /evidence="ECO:0000269|PubMed:30135643"
FT   MUTAGEN         470
FT                   /note="H->A: Loss of palmitoyl thioesterase activity. No
FT                   effect on carnitine O-palmitoyltransferase inactivity."
FT                   /evidence="ECO:0000269|PubMed:16651524,
FT                   ECO:0000269|PubMed:30135643"
FT   MUTAGEN         474
FT                   /note="D->A: Loss of palmitoyl thioesterase activity."
FT                   /evidence="ECO:0000269|PubMed:30135643"
FT   CONFLICT        58
FT                   /note="S -> G (in Ref. 3; BAF82402)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        375..378
FT                   /note="HEEH -> RTRG (in Ref. 6; CAD38561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        542
FT                   /note="D -> G (in Ref. 3; BAB85068)"
FT                   /evidence="ECO:0000305"
FT   TURN            13..15
FT                   /evidence="ECO:0007829|PDB:2M76"
FT   HELIX           25..48
FT                   /evidence="ECO:0007829|PDB:2M76"
SQ   SEQUENCE   803 AA;  90989 MW;  96C2AE6ED0DEC705 CRC64;
     MAEAHQAVGF RPSLTSDGAE VELSAPVLQE IYLSGLRSWK RHLSRFWNDF LTGVFPASPL
     SWLFLFSAIQ LAWFLQLDPS LGLMEKIKEL LPDWGGQHHG LRGVLAAALF ASCLWGALIF
     TLHVALRLLL SYHGWLLEPH GAMSSPTKTW LALVRIFSGR HPMLFSYQRS LPRQPVPSVQ
     DTVRKYLESV RPILSDEDFD WTAVLAQEFL RLQASLLQWY LRLKSWWASN YVSDWWEEFV
     YLRSRNPLMV NSNYYMMDFL YVTPTPLQAA RAGNAVHALL LYRHRLNRQE IPPTLLMGMR
     PLCSAQYEKI FNTTRIPGVQ KDYIRHLHDS QHVAVFHRGR FFRMGTHSRN SLLSPRALEQ
     QFQRILDDPS PACPHEEHLA ALTAAPRGTW AQVRTSLKTQ AAEALEAVEG AAFFVSLDAE
     PAGLTREDPA ASLDAYAHAL LAGRGHDRWF DKSFTLIVFS NGKLGLSVEH SWADCPISGH
     MWEFTLATEC FQLGYSTDGH CKGHPDPTLP QPQRLQWDLP DQIHSSISLA LRGAKILSEN
     VDCHVVPFSL FGKSFIRRCH LSSDSFIQIA LQLAHFRDRG QFCLTYESAM TRLFLEGRTE
     TVRSCTREAC NFVRAMEDKE KTDPQCLALF RVAVDKHQAL LKAAMSGQGV DRHLFALYIV
     SRFLHLQSPF LTQVHSEQWQ LSTSQIPVQQ MHLFDVHNYP DYVSSGGGFG PADDHGYGVS
     YIFMGDGMIT FHISSKKSST KTDSHRLGQH IEDALLDVAS LFQAGQHFKR RFRGSGKENS
     RHRCGFLSRQ TGASKASMTS TDF
//
